Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by conspiTheoryon Nov 25, 2011 11:43am
348 Views
Post# 19267321

wonder how many characters in the subject?

wonder how many characters in the subject? here we go from our last friend dollarchamp.https://www.businesswire.com/news/home/20110413005979/en/Research-Markets-Bladder-Cancer---Global-DrugGemcitabine was the top-selling drug in the bladder cancer therapeuticsmarket in 2010. The other leading drugs in the market in 2001 were BCGtherapy and methotrexate which registered sales of $55m and $57m. In2010, gemcitabine was the leading drug in the bladder cancertherapeutics market, with sales of $170m. Methotrexate and BCG therapywere the other leading therapies with sales of $145m and $131m. Between2010 and 2020, three promising therapies, Javlor (vinflunine), Urocidin(intravesical formulation of Mycobacterial cell wall-DNA complex (MCC))and EOquin (apaziquone), are expected to hit the market. Between 2010and 2020, the market is expected to be led by Urocidin, with forecastsales of $386m.Post #29597269 side effect from gemcitabine:https://www.google.ca/url?sa=t&rct=j&q=gemcitabine%20side%20effects%20pdf%20bc%20cancer&source=web&cd=1&ved=0CBsQFjAA&url=http%3A%2F%2Fwww.bccancer.bc.ca%2FNR%2Frdonlyres%2F61DCBA09-705A-485C-9058-05B892064E80%2F50942%2Fgemcitabine_monograph_6June2011.pdf&ei=WMTPTq3WCYOIiALotOG6BQ&usg=AFQjCNGQUpibRdIvbAXvx_It-vqkdxAQdw&cad=rja
Bullboard Posts